Cytek Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact

Anniversary Milestone Highlights Expanded Manufacturing Capacity, Stronger Asia-Pacific Presence, and Measurable Contributions to Global Supply Chain Resilience

FREMONT, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- One year after opening its 8,500-square-foot Singapore facility, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) is marking a major milestone in its Asia-Pacific (APAC) expansion. Serving as a strategic hub supporting customers across APAC and worldwide, the Singapore facility has contributed to Cytek’s growth over the past 12 months, significantly enhancing Cytek’s manufacturing capacity, regional service and training capabilities, and reinforcing global supply chain resilience while helping mitigate geopolitical and trade-related risks.

As life sciences research continues to expand worldwide, Cytek’s Singapore operations stand as a critical global component of its regional manufacturing strategy, advancing scientific discovery and supporting sustained business growth in one of the fastest-growing regions for biomedical research.

“Establishing operations in Singapore has been a transformative step for Cytek,” said Wenbin Jiang, Ph.D., CEO of Cytek Biosciences. “In just one year, the facility has strengthened our manufacturing footprint, improved supply chain agility, and deepened our engagement with customers across APAC. This milestone reflects our commitment to investing in infrastructure that empowers scientists to move discovery forward.”

Driven by the growing global use of cellular analysis in immunology, immuno-oncology, infectious diseases, cancer diagnosis and cancer drug development, Cytek’s Singapore expansion was designed to address rising demand for cell analysis solutions. Over the past year, the facility has enhanced production scalability and reduced delivery times in key markets. The site also features a dedicated service and training center that provides hands-on, regional access to Cytek instruments and advanced technical expertise in addition to its manufacturing operation.

“Cytek Biosciences’ new facility has been a welcome addition to Singapore’s MedTech ecosystem,” said Marcus Dass, Senior Vice President and Head, Global Enterprises, Singapore Economic Development Board. “The investment strengthens our advanced manufacturing capabilities as well as contributes to life sciences research through the company’s cell analysis technologies. We are also heartened to hear that Cytek Biosciences is working with our Institutes of Higher Learning and Research Institutes to drive innovation and talent development.”

About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP

) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Muse Micro system; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available.

Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).

Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Muse, Amnis and Guava are trademarks of Cytek Biosciences, Inc.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website as a channel of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website in addition to following its SEC filings, news releases, public conference calls and webcasts.